Novavax Inc (NVAX) stock
NVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.47−0.25 (-3.24%)
Close on Nov 20, 2026Market cap $1.23BP/E –Yield –
Novavax free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Novavax's free cash flow for the twelve months ending Sep 30, 2022 was -$722.93M, down 259.4% year over year. For fiscal 2021 it was $265.46M. The highest annual figure on record is $265.46M in fiscal 2021.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | $265.46M | – |
| FY2020 | Dec 31, 2020 | -$97.16M | – |
| FY2019 | Dec 31, 2019 | -$138.48M | – |
| FY2018 | Dec 31, 2018 | -$186.20M | – |
| FY2017 | Dec 31, 2017 | -$148.67M | – |
| FY2016 | Dec 31, 2016 | -$276.97M | – |
| FY2015 | Dec 31, 2015 | -$144.36M | – |
| FY2014 | Dec 31, 2014 | -$74.28M | – |
| FY2013 | Dec 31, 2013 | -$51.14M | – |
| FY2012 | Dec 31, 2012 | -$22.57M | – |
| FY2011 | Dec 31, 2011 | -$24.24M | – |
| FY2010 | Dec 31, 2010 | -$34.41M | – |
| FY2009 | Dec 31, 2009 | -$33.58M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2022 | Sep 30, 2022 | -$63.34M | – |
| Q2 FY2022 | Jun 30, 2022 | -$195.48M | -251.2% |
| Q1 FY2022 | Mar 31, 2022 | -$105.34M | -116.2% |
| Q4 FY2021 | Dec 31, 2021 | -$358.77M | – |
| Q3 FY2021 | Sep 30, 2021 | -$154.33M | – |
| Q2 FY2021 | Jun 30, 2021 | $129.26M | +15.5% |
| Q1 FY2021 | Mar 31, 2021 | $649.30M | – |
| Q4 FY2020 | Dec 31, 2020 | -$170.58M | – |
| Q3 FY2020 | Sep 30, 2020 | -$15.22M | – |
| Q2 FY2020 | Jun 30, 2020 | $111.87M | – |
| Q1 FY2020 | Mar 31, 2020 | -$23.23M | – |
| Q4 FY2019 | Dec 31, 2019 | -$23.96M | – |
| Q3 FY2019 | Sep 30, 2019 | -$32.62M | – |
| Q2 FY2019 | Jun 30, 2019 | -$30.49M | – |
| Q1 FY2019 | Mar 31, 2019 | -$51.41M | – |
| Q4 FY2018 | Dec 31, 2018 | -$45.78M | – |
| Q3 FY2018 | Sep 30, 2018 | -$33.91M | – |
| Q2 FY2018 | Jun 30, 2018 | -$40.28M | – |
| Q1 FY2018 | Mar 31, 2018 | -$66.23M | – |
| Q4 FY2017 | Dec 31, 2017 | -$44.05M | – |
| Q3 FY2017 | Sep 30, 2017 | -$45.40M | – |
| Q2 FY2017 | Jun 30, 2017 | -$13.64M | – |
| Q1 FY2017 | Mar 31, 2017 | -$45.58M | – |
| Q4 FY2016 | Dec 31, 2016 | -$67.74M | – |
| Q3 FY2016 | Sep 30, 2016 | -$66.32M | – |
See a number that looks wrong?